HANSIZHUANG has become one of the pioneering anti-PD-1 mAb for the “pan-cancer” treatment of MSI-H solid tumors in China. Up to date, HANSIZHUANG has been approved by the NMPA for the treatment of MSI-...
Developers wishing to access the structured reporting templates via an application programming interface (API) can review the documentation available athttp://www.radreport.org/dev Open Template Library Radiologists are encouraged to browse and share ...
In April 2022, the US Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for HANSIZHUANG for the treatment of SCLC. Based on the positive feedback from FDA Biologics License Application...
Developers wishing to access the structured reporting templates via an application programming interface (API) can review the documentation available athttp://www.radreport.org/dev Open Template Library Radiologists are encouraged to browse and share ...
Teams of radiology experts, subspecialty radiology societies, and leading radiology departments have contributed a wealth of best-practices radiology report templates. The templates are free and not subject to license restrictions on their reuse.
Teams of radiology experts, subspecialty radiology societies, and leading radiology departments have contributed a wealth of best-practices radiology report templates. The templates are free and not subject to license restrictions on their reuse.
Teams of radiology experts, subspecialty radiology societies, and leading radiology departments have contributed a wealth of best-practices radiology report templates. The templates are free and not subject to license restrictions on their reuse. These ...